Trial of Darbepoetin plus slow-release intravenous iron to decrease transfusions and improve iron status and neurodevelopment in preterm infants

达贝泊汀联合缓释静脉铁剂减少输血、改善早产儿铁状态和神经发育的试验

基本信息

  • 批准号:
    10340574
  • 负责人:
  • 金额:
    $ 49.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-08 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

Preterm infants are at high risk for both transfusions and iron deficiency, both of which may independently contribute to poor neurodevelopmental outcomes. On average, infants less than 1000 gm require 4 to 5 blood transfusions during their initial hospitalization. Darbepoetin (Darbe) can increase the number of infants who remain transfusion-free, and for those who do require transfusions, can decrease the number of transfusions, cumulative volume of blood transfused, and unique donor exposures. However, the use of Darbe increases iron utilization, and treated infants may become progressively iron deficient with oral iron supplementation alone. When iron supply does not meet the iron demand of the rapidly expanding RBC mass, first iron stores in the liver and then non-storage iron in other tissues (including brain) will be compromised. This is of particular concern for preterm infants since iron is required for normal brain development, including such processes as myelination, dendritogenesis, production and degradation of neurotransmitters, and to sustain the brain’s high metabolic rate. Thus, iron deficiency during fetal and early postnatal months can result in irreversible neurodevelopmental abnormalities despite later iron repletion. Our overarching goal is to develop a therapeutic pathway to minimize transfusions while maintaining iron sufficiency, thereby optimizing developmental outcomes. We hypothesize that combined treatment of infants < 32 completed weeks of gestation with Darbe plus one of two slow-release intravenous (IV) iron preparations, ferumoxytol (FMX) or low molecular weight iron dextran (LMW-ID) will 1) be safe, 2) decrease or eliminate transfusions, 3) increase hematocrit, 4) maintain iron sufficiency, and 5) improve neurodevelopment. We further hypothesize that when compared to oral iron supplementation (standard care), IV iron will be better tolerated, with less effect on the gut microbiome. An advantage of using these slow-release IV iron preparations is that fewer, higher doses of iron are needed to prevent or treat iron deficiency. For example, an anemic iron deficient pregnant woman can be treated with a single dose of 1000 mg IV compared to 5 IV doses of iron sucrose. Because FMX and LMW-ID have not been tested in neonates, in Aim 1 we will compare these two drugs and evaluate total dosage needed to maintain iron sufficiency while being treated with Darbe. Starting doses will be 10 mg/kg and 20 mg/kg, repeated as needed to maintain ferritin >75 mcg/L. In Aim 2 we will compare the safety, efficacy and tolerance of the combined approach of using Darbe + IV iron (N=80) with standard care (oral iron supplements up to 12 mg/kg/day, N=40). Evaluation will include safety, gastrointestinal tolerance, and efficacy. The effect of oral compared to IV iron on the microbiome will be evaluated. The primary outcome will be hematocrit, transfusion burden and iron status at hospital discharge. In Aim 3, the long-term neurodevelopmental outcome of the 3 groups (Darbe + FMX, Darbe + LMW-ID, oral iron only) will be evaluated up to 2 years of age. We anticipate demonstrating the feasibility and potential benefit of Darbe plus slow-release IV iron to decrease transfusions, maintain iron sufficiency and improve neurodevelopmental outcomes.
早产儿输血和缺铁的风险都很高,这两种情况都可能独立存在

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sandra E Juul其他文献

Does Central Nervous System Injury Result in Increased Cerebral Spinal Fluid Erythropoietin Concentration in Neonates and Children?
  • DOI:
    10.1203/00006450-199904020-01576
  • 发表时间:
    1999-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Susan A Stallings;Robert D Christensen;Sandra E Juul
  • 通讯作者:
    Sandra E Juul
The emLancet Child & Adolescent Health/em Commission on the future of neonatology
  • DOI:
    10.1016/s2352-4642(25)00106-3
  • 发表时间:
    2025-08-01
  • 期刊:
  • 影响因子:
    15.500
  • 作者:
    Daniele De Luca;Neena Modi;Peter Davis;Satoshi Kusuda;Saskia N de Wildt;Martin Keszler;Allyah Abbas-Hanif;Sandra E Juul;Mark Turner;J Jane Pillow;Nikki Robertson;Manuel Sanchez-Luna;David G Tingay;Alexandra Benachi;Flavia Bustreo;Gianluca Ianiro;Mark Hanson;Jan Deprest;Paolo De Coppi;Agnes van den Hoogen;Steven H Abman
  • 通讯作者:
    Steven H Abman
Immunohistochemical Localization of Erythropoietin (Epo) and Erythropoietin Receptor (EpoR) in Developing Human Brain ♦ 267
促红细胞生成素(Epo)和促红细胞生成素受体(EpoR)在发育中的人脑中的免疫组织化学定位♦267
  • DOI:
    10.1203/00006450-199704001-00287
  • 发表时间:
    1997-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Sandra E Juul;Anthony T Yachnis;Amyn M Rojiani;Robert D Christensen
  • 通讯作者:
    Robert D Christensen
The Distribution of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and its Receptor (GM-CSF-R) in the Developing Human Fetus ♦ 255
粒-巨噬细胞集落刺激因子(GM-CSF)及其受体(GM-CSF-R)在发育中的人胎儿中的分布♦255
  • DOI:
    10.1203/00006450-199804001-00276
  • 发表时间:
    1998-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    J Benjamin Dame;Anthony T Yachnis;Sandra E Juul
  • 通讯作者:
    Sandra E Juul
Neonatal Anemia.
新生儿贫血。
  • DOI:
    10.2174/1573396319666221121140627
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Kendell R German;Sandra E Juul
  • 通讯作者:
    Sandra E Juul

Sandra E Juul的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sandra E Juul', 18)}}的其他基金

13th Hershey Developmental Brain Injury Conference
第十三届好时发育性脑损伤会议
  • 批准号:
    10467344
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
Trial of Darbepoetin plus slow-release intravenous iron to decrease transfusions and improve iron status and neurodevelopment in preterm infants
达贝泊汀联合缓释静脉铁剂减少输血、改善早产儿铁状态和神经发育的试验
  • 批准号:
    10662182
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
Intellectual and Developmental Disabilities Research Center
智力与发育障碍研究中心
  • 批准号:
    10661668
  • 财政年份:
    2020
  • 资助金额:
    $ 49.23万
  • 项目类别:
High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) CCC
高剂量促红细胞生成素治疗窒息和脑病 (HEAL) CCC
  • 批准号:
    9174860
  • 财政年份:
    2016
  • 资助金额:
    $ 49.23万
  • 项目类别:
A novel ferret model of preterm encephalopathy
一种新型雪貂早产脑病模型
  • 批准号:
    9111076
  • 财政年份:
    2015
  • 资助金额:
    $ 49.23万
  • 项目类别:
Preterm Epo Neuroprotection Trial (PENUT Trial) CCC
早产儿 Epo 神经保护试验(PENUT 试验)CCC
  • 批准号:
    8503912
  • 财政年份:
    2013
  • 资助金额:
    $ 49.23万
  • 项目类别:
Preterm Epo Neuroprotection Trial (PENUT Trial) CCC
早产儿 Epo 神经保护试验(PENUT 试验)CCC
  • 批准号:
    8841021
  • 财政年份:
    2013
  • 资助金额:
    $ 49.23万
  • 项目类别:
Biomarkers of Neonatal Encephalopathy in a Nonhuman Primate Model
非人灵长类动物模型中新生儿脑病的生物标志物
  • 批准号:
    9105736
  • 财政年份:
    2013
  • 资助金额:
    $ 49.23万
  • 项目类别:
Biomarkers of Neonatal Encephalopathy in a Nonhuman Primate Model
非人灵长类动物模型中新生儿脑病的生物标志物
  • 批准号:
    8520911
  • 财政年份:
    2013
  • 资助金额:
    $ 49.23万
  • 项目类别:
Preterm Epo Neuroprotection Trial (PENUT Trial) CCC
早产儿 Epo 神经保护试验(PENUT 试验)CCC
  • 批准号:
    8771809
  • 财政年份:
    2013
  • 资助金额:
    $ 49.23万
  • 项目类别:

相似海外基金

The European Hydrogen Academy (HyAcademy.EU)
欧洲氢学院 (HyAcademy.EU)
  • 批准号:
    10110448
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    EU-Funded
REU Site: Summer Academy in Sustainable Manufacturing
REU 网站:可持续制造夏季学院
  • 批准号:
    2348993
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Standard Grant
GP-UP Ocean Research College Academy Engagement in Authentic Geoscience Learning Ecosystems (ORCA-EAGLE)
GP-UP 海洋研究学院学院参与真实的地球科学学习生态系统 (ORCA-EAGLE)
  • 批准号:
    2326962
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Standard Grant
HyAcademy.EU: The European Hydrogen Academy
HyAcademy.EU:欧洲氢学院
  • 批准号:
    10101978
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    EU-Funded
Conference: Cyberinfrastructure Leadership Academy: Team Science and Grand Challenges
会议:网络基础设施领导学院:团队科学和重大挑战
  • 批准号:
    2414440
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Standard Grant
Travel: NSF Student Travel Grant for 2024 Academy of Management Annual Meeting (AOM)
旅行:2024 年管理学院年会 (AOM) 的 NSF 学生旅行补助金
  • 批准号:
    2420866
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Standard Grant
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
  • 批准号:
    498310
  • 财政年份:
    2024
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Operating Grants
Semiconductor Higher Technical Skills Academy Wales: Recruitment, Retention & Upskilling
威尔士半导体高等技术技能学院:招聘、保留
  • 批准号:
    10076049
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Collaborative R&D
Simulation Academy at Yale: Youth Entering Science (SAY-YES!)
耶鲁大学模拟学院:青年进入科学(说是!)
  • 批准号:
    10663646
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
Collaborative Research: GP-GO: Climate Leaders Academy: a professional development opportunity in the geosciences
合作研究:GP-GO:气候领袖学院:地球科学领域的专业发展机会
  • 批准号:
    2232215
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了